Status:
COMPLETED
Salvage Surgery for Patients With Metastatic GIST With Rego
Lead Sponsor:
Chang Gung Memorial Hospital
Conditions:
Gastrointestinal Stromal Tumors
Metastasis
Eligibility:
All Genders
20+ years
Brief Summary
Some researches have shown surgery may acquire progression-free (PFS) benefit for selected patients with metastatic gastrointestinal stromal tumor (GIST) who received first-line imatinib and second-li...
Detailed Description
Between 2014 and 2019, 41 metastatic GIST patients received regorafenib therapy. 35 out of 41 metastatic GIST patients who were on regorafenib therapy facing progression and 15 experienced local progr...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients who is taking regorafenib after treatment failure by 1st line and 2nd line tyrosine kinase, namely Imatinib and Sunitinib.
- Patients with aforementioned condition and is facing local progression of disease or stationary disease.
- Exclusion criteria
- Systemic progression of disease
- ASA classification \> 3
Exclusion
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2020
Estimated Enrollment :
41 Patients enrolled
Trial Details
Trial ID
NCT04343456
Start Date
January 1 2014
End Date
February 28 2020
Last Update
April 14 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chang Gung Memorial Hospital Linkou Branch
Taoyuan District, Taiwan, 333